Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 Aug;122(2 Pt 2):487-489.
doi: 10.1097/AOG.0b013e31828e2612.

Eculizumab for atypical hemolytic uremic syndrome in pregnancy

Gianluigi Ardissino  1 , Manuela Wally Ossola, Giulia Maria Baffero, Angelo Rigotti, Massimo Cugno
Affiliations
Case Reports

Eculizumab for atypical hemolytic uremic syndrome in pregnancy

Gianluigi Ardissino et al. Obstet Gynecol. 2013 Aug.

Abstract

Background: Atypical hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy often caused by mutations in complement genes. During pregnancy, disease outcome is poor both for mother and fetus. Since 2009, the humanized monoclonal antibody eculizumab has been successfully used in the treatment of atypical HUS in nonpregnant patients.

Case: A 26-year-old woman with a homozygous mutation in complement factor H developed a relapse of atypical HUS at 17 weeks of gestation in her first pregnancy. Because the disease remained active despite multiple plasma exchanges, eculizumab was started at 26 weeks of gestation. It was well tolerated and has led to remission and to the delivery of a healthy neonate.

Conclusion: Eculizumab may be useful for the treatment of atypical HUS during pregnancy.

PubMed Disclaimer

References

    1. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60.
    1. Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol 2010;25:2431–42.
    1. Fakhouri F, Roumenina L, Provot F, Sallée M, Caillard S, Couzi L, et al.. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010;21:859–67.
    1. Clark WF. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange. Semin Dial 2012;25:214–9.
    1. Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, et al.. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996;33:1389–401.

Publication types

LinkOut - more resources